Prostate cancer patients seek out mind-body care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Marcia Prenguber, ND, FABNO, director of integrative care at Goshen Center for Cancer Care in Indiana, said more than 75% of patients use complementary and alternative medicine, yet remain reluctant to tell their oncologists about it. Dr. Prenguber said she does not consider complementary medicine as an alternative to standard treatment, but as a way to tailor healing to the individual.

Marcia Prenguber, ND, FABNO, director of integrative care at Goshen Center for Cancer Care in Indiana, said more than 75% of patients use complementary and alternative medicine, yet remain reluctant to tell their oncologists about it. Dr. Prenguber said she does not consider complementary medicine as an alternative to standard treatment, but as a way to tailor healing to the individual.

“We combine conventional treatments with complementary care to determine what’s best for patients,” she said. “The relationship among providers and with patients ensures that the whole person, not just his prostate, is the center of care.”

J. Craig Gordon, BSN, is the prostate care coordinator at Waukesha Memorial Hospital in Wisconsin. He leads support groups once a month so that patients have continued access to assistance in between physician appointments and also offers one-on-one counseling. “I help patients navigate the system-from diagnosis all the way through long-term follow up,” he said.

The purpose of these meetings is to review pros and cons of treatment options, assess patient stress level, and offer coping mechanisms, Mr. Gordon explained.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Related Content